The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Neovasc Says Co’s Reducer Featured In Polish Heart Journal
Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company") today announced that the Neovasc Reducer™ ("Reducer") is featured in an article published
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
Neovasc Highlights Publication Of REDUCER-I Study In EuroIntervention Journal
- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, "Coronary sinus narrowing for the treatment of refractory
Why Are Neovasc Shares Moving Higher On Thursday?
The FDA approved the Investigational Device Exemption for Neovasc Inc’s (NASDAQ:NVCN) COSIRA-II IDE Clinical Trial regarding the Neovasc Reducer. Related Content: Real-World Study…
Neovasc Announces Submission Of COSIRA-II Protocol Supplement To FDA
Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food
Neovasc Q2 EPS $(0.13) Misses $(0.05) Estimate, Sales $633.00K Miss $1.16M Estimate
Neovasc (NASDAQ:NVCN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 83.95 percent increase over losses of $(0.81) per share from the same
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)